CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus

Zhao, Kaikai; Ma, Lin; Feng, Lei; Huang, Zhaoqin; Meng, Xiangjiao; Yu, Jinming

doi:10.3389/fmolb.2020.608404

“…A total of 862 papers were initially identified. After removing duplicate literature and reading the title, abstract, and full text, according to the study's inclusion and exclusion requirements, eight papers were included [ 9 , 10 , 15 – 17 , 19 , 21 , 25 ]. The process and results of the literature screening are presented in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Five studies explicitly documented reported HRs and 95% CIs, while the other three studies calculated HR and 95% CI from the survival curves. All studies evaluated the correlation between TIGIT expression and OS in patients with solid tumors [ 9 , 10 , 15 – 17 , 19 , 21 , 25 ], and three studies evaluated the relationship between TIGIT expression and PFS in patients with solid tumors [ 16 , 21 , 25 ]. Zhou et al [ 9 ] and Liang et al [ 10 ] reported the relationship between TIGIT expression and DFS and RFS, respectively.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis

Xiao

¹

,

Xiao

²

,

Li

³

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

Background. T cell immunoglobulin and ITIM domain (TIGIT) is a recently identified immunosuppressive receptor. The expression levels of TIGIT affect the prognosis of patients with solid tumors. To fully comprehend the role of TIGIT on the prognosis of patients with solid tumors, we conducted a meta-analysis. Methods. We performed an online search of PubMed, Embase, Web of Science (WOS), and MEDLINE databases for literature published till March 31, 2021. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the literature, and Stata 16.0 and Engauge Digitizer 4.1 software were used for data analysis. Results. Our literature search identified eight papers comprising 1426 patients with solid tumors. Increased expression of TIGIT was associated with poor prognosis. High expression of TIGIT was a risk factor for overall survival (OS) { hazard ratio HR = 1.66 , 95% confidence interval (CI) [1.26, 2.20], P < 0.001 } and progression-free survival (PFS) ( HR = 1.44 , 95% CI [1.15, 1.81], P = 0.01 ). We performed subgroup analysis to explore the source of heterogeneity, colorectal cancer ( HR = 2.07 , 95% CI [0.23, 18.82], P = 0.518 ), lung cancer ( HR = 1.29 , 95% CI [0.96, 1.72], P = 0.094 ), esophageal cancer ( HR = 1.70 , 95% CI [1.20, 2.40], P = 0.003 ), and other cancers ( HR = 1.83 , 95% CI [1.25, 2.68], P = 0.002 ). In addition to cancer type, expression location, sample size, and different statistical analysis methods are also considered the possible causes of heterogeneity between studies. Funnel plots suggested no publication bias for OS ( P = 0.902 ), and Egger’s test supported this conclusion ( P = 0.537 ). Conclusion. TIGIT expression was associated with OS and PFS in patients with solid tumors. Patients with elevated TIGIT expression have a shorter OS and PFS, and TIGIT expression could be a novel biomarker for prognosis prediction and a valuable therapeutic target for solid tumors.

show abstract

“…An association of increased CD155 expression with a poor prognosis has been noted in several malignant tumors [ 147 , 148 , 149 , 150 ]. In GC, an association of increased expression of CD155 with poor OS was observed [ 131 , 151 ].…”

Section: Immune Checkpoint Expression In Connection With Clinical Features and The Therapeutic Efficacy Of Their Inhibitionmentioning

confidence: 99%

“…There is evidence of an association of CD155 expression with clinical characteristics of the tumor. Thus, CD155 expression in some types of solid tumors was significantly associated with tumor size, depth of invasion, and TNM stage [ 147 , 148 , 152 , 153 ]. In GC, increased expression of sCD155 in blood serum was associated with the TNM stage [ 154 ].…”

Section: Immune Checkpoint Expression In Connection With Clinical Features and The Therapeutic Efficacy Of Their Inhibitionmentioning

confidence: 99%

Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis

Mansorunov

¹

,

Apanovich

²

,

Апанович

³

et al. 2021

View full text Add to dashboard Cite

To increase the effectiveness of anticancer therapy based on immune checkpoint (IC) inhibition, some ICs are being investigated in addition to those used in clinic. We reviewed data on the relationship between PD-L1, B7-H3, B7-H4, IDO1, Galectin-3 and -9, CEACAM1, CD155, Siglec-15 and ADAM17 expression with cancer development in complex with the results of clinical trials on their inhibition. Increased expression of the most studied ICs—PD-L1, B7-H3, and B7-H4—is associated with poor survival; their inhibition is clinically significant. Expression of IDO1, CD155, and ADAM17 is also associated with poor survival, including gastric cancer (GC). The available data indicate that CD155 and ADAM17 are promising targets for immune therapy. However, the clinical trials of anti-IDO1 antibodies have been unsatisfactory. Expression of Galectin-3 and -9, CEACAM1 and Siglec-15 demonstrates a contradictory relationship with patient survival. The lack of satisfactory results of these IC inhibitor clinical trials additionally indicates the complex nature of their functioning. In conclusion, in many cases it is important to analyze the expression of other participants of the immune response besides target IC. The PD-L1, B7-H3, B7-H4, IDO1 and ADAM17 may be considered as candidates for prognosis markers for GC patient survival.

show abstract

“…Moreover, this upregulation is associated with an increased metastatic capacity of cancer cells [4]. Furthermore, PVR is overexpressed in several types of cancers, including serous ovarian cancer, colorectal carcinoma, hepatocellular carcinoma, lung adenocarcinoma, esophageal small cell carcinoma, and cholangiocarcinoma [5][6][7][8][9][10], and highly expressed in bone marrow cells in multiple myeloma (MM) [11]. Thus, the effects of PVR expression on progression and metastasis in patients with MM are of interest.…”

Section: Introductionmentioning

confidence: 99%

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma

Lee

¹

,

Kim

²

,

Kang

³

et al. 2022

Preprint

4

0

View full text Add to dashboard Cite

Poliovirus receptor (PVR, CD155) is upregulated during tumor progression, and PVR expression is associated with poor prognosis in patients with cancer; however, prognostic implications for PVR in multiple myeloma (MM) have not been investigated. We assessed PVR expression in bone marrow samples of 125 patients via immunohistochemistry (IHC) and in those of 22 patients via enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction. Additionally, we evaluated TIGIT levels in bone marrow CD8+ T cells and natural killer cells in 14 patients using flow cytometry. Soluble PVR and TIGIT levels in 22 patients were measured using ELISA. PVR clinical and prognostic significance were assessed using a histoscore via IHC. PVR was highly expressed in patients with MM, and membrane PVR expression showed significant correlation with soluble PVR levels. Moreover, PVR expression was significantly associated with Revised-International Staging System stage, presence of extramedullary plasmacyoma and bone lesions, percentage of bone marrow plasma cells, and β2-microglobulin levels, suggesting a possible role in advanced stage and metastasis. Furthermore, we found that TIGIT expression was significantly correlated with the percentage of bone marrow plasma cells. Patients with high PVR expression had significantly shorter overall and progression-free survival, and PVR expression was identified as an independent prognostic factor for poor survival in MM. These findings indicated that PVR expression is associated with MM stage and poor prognosis, suggesting PVR expression as a potential prognostic marker for MM.

show abstract

CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus

Cited by 22 publications

References 48 publications

Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis

Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis

Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma

Contact Info

Product

Resources

About